Corcept Therapeutics forecasts 2026 revenue of $1.1 billion-$1.2 billion
CORT•Corcept Therapeutics forecast 2026 revenue of $1.1 billion to $1.2 billion. Third-quarter revenue was $341 million, including $249 million from Korlym and $91 million from Lifyorli; cash totaled $662 million.
1. Revenue forecast and results
Corcept Therapeutics forecast 2026 revenue of $1.1 billion to $1.2 billion. Third-quarter revenue totaled $341 million, up from $256 million in the second quarter; Korlym generated $249 million and Lifyorli contributed $91 million. Cash stood at $662 million at the end of the third quarter.
